Current Report Filing (8-k)
January 08 2018 - 6:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported):
January 8, 2018
IOVANCE
BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
|
(State of Incorporation)
|
|
001-36860
|
|
75-3254381
|
Commission File Number
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
999 Skyway Road, Suite 150
|
|
|
San Carlos, California
|
|
94070
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
|
|
|
(650) 260-7120
|
(Registrant’s Telephone Number, Including Area Code)
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging
growth company
¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
Iovance Biotherapeutics, Inc. (the “Company”)
from time to time makes presentations at healthcare conferences and to analysts, current stockholders, and others. A copy of the
Company’s presentation that it intends to use during January 2018 is furnished as Exhibit 99.1 to this current report on
Form 8-K and incorporated by reference herein.
On December 15, 2017, a purported shareholder derivative complaint,
Kevin Fong v. Manish Singh, et
al.
(C.A. No. 17-1806), was filed against the Company, as nominal defendant, and certain of the Company’s current and
former officers and directors, and others, as defendants, in the U.S. District Court for the District of Delaware. The complaint
alleges breaches of fiduciary duties, unjust enrichment, and violations of Section 14(a) of the Securities Exchange Act of 1934
and Rule 14a-9 promulgated thereunder arising from the Securities and Exchange Commission’s investigation in the
In the
Matter of Certain Stock Promotions
matter and the Company’s April 10, 2017 settlement thereof, and seeks unspecified damages on behalf
of the Company and injunctive relief.
The Company intends to vigorously defend
against the foregoing complaint. Based on the very early stage of the litigation, it is not possible to estimate the amount or
range of possible loss that might result from an adverse judgment or a settlement of the matter.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 8, 2018
|
IOVANCE BIOTHERAPEUTICS, INC.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ MARIA FARDIS
|
|
|
|
Maria Fardis, Chief Executive Officer
|
|
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Iovance Biotherapeutics (NASDAQ:IOVA)
Historical Stock Chart
From Apr 2023 to Apr 2024